Vividion Therapeutics, Inc.

37 articles about Vividion Therapeutics, Inc.

• Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

  2/6/2024

  Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.

• Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune

  11/21/2023

  Vividion Therapeutics, Inc. has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row.

• Vividion Therapeutics Names Shawn Rose as Chief Development Officer

  9/7/2023

  Vividion Therapeutics, Inc. and a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Shawn Rose, M.D. Ph.D., has joined the company as Chief Development Officer, Immunology, reporting to our Chief Executive Officer, Aleksandra Rizo.

• Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer

  3/23/2023

  Vividion Therapeutics, Inc. today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.

• Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2022’ Award Winner by the San Diego Union-Tribune

  11/21/2022

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies and advanced science to find new solutions for devastating cancers and immune disorders, has been recognized as a Top Workplaces 2022 award winner by the San Diego Union-Tribune.

• Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

  10/12/2022

  Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.

• 

  Bayer's Vividion Bets up to $930M for Tavros Oncology Partnership

  10/12/2022

  Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
• 

  Legendary Bayer is Reinventing its Story with Cell and Gene Therapy

  1/12/2022

  Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
• 

  Avilar Debuts to Pioneer Extracellular Protein Degradation

  11/18/2021

  Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.

• Vividion Therapeutics Announces Formation of Scientific Advisory Board

  9/22/2021

  Vividion Therapeutics, Inc. today announced the formation of a scientific advisory board (SAB) comprised of industry leaders in oncology, immunology, drug development and chemical biology.

• Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics

  8/5/2021

  Versant Ventures announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments.

• Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics

  8/5/2021

  Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform

• 

  Bayer Drops $2 Billion to Drug the Undruggable

  8/5/2021

  Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments. 

• Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target

  6/24/2021

  Vividion Therapeutics, Inc. today announced that it has earned its first milestone payment related to its exclusive worldwide collaboration, option and license agreement with Roche.

• Vividion Therapeutics Appoints Christine Siu to Board of Directors

  5/4/2021

  Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.

• Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments

  4/20/2021

  Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.

• Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development

  3/30/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Patricia “Patty” Allen, who has served as acting chief financial officer of Vividion since January 2021, has joined the company as full-time CFO and that Brian Koh, M.D., has been appointed as head of translational sciences

• Vividion Appoints Catherine Friedman to Board of Directors

  3/24/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.

• Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

  2/24/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the completion of a $135 million Series C financing, co-led by new investors, Logos Capital and Boxer Capital of Tavistock Group.

• Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer

  11/23/2020

  Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.